SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh long-term bullish sentiment against ongoing consolidation and frustration over price stagnation. The discourse is fueled by a mix of speculative trading activity and interest in broader crypto market shifts, with many participants actively discussing potential breakout catalysts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community highlights its multi-year track record and organic growth on the Solana network while actively encouraging others to load their bags. Participants are rallying behind the ticker with memes and dad jokes, emphasizing the project's presence on the Jupiter strict list as a core point of interest.

ETHGas is a Blockspace Infrastructure protocol that decomposes Ethereum blockspace into tradable, composable block units, enabling real‑time block production and laying the foundation for a crypto‑native commodities market for gas. By restructuring gas as a financial primitive, ETHGas unlocks: - Faster block times (sub‑second confirmations vs 12‑second Ethereum blocks) through real‑time sequencing. - A futures/forward market for gas, enabling the creation of a native Ethereum yield curve. - Gas abstraction for end users via the Open Gas Initiative, removing gas volatility and shifting costs to protocols. - Commoditization of blockspace, similar to energy or metals markets in traditional finance.

ETHGas

GWEI is gaining attention as a momentum-driven Ethereum ecosystem token following new listings on major exchanges and growing optimism surrounding upcoming legislative clarity in the crypto sector. Community members are actively discussing its price resilience and staking utility while monitoring broader market catalysts for a potential bull cycle.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with community members actively discussing its potential for a weekend rally and coordinated "dumb sends" to drive market cap growth. Supporters are highlighting the active involvement of the developer, who is incentivizing engagement through periodic airdrops to holders while encouraging the community to ignore market dips and focus on long-term accumulation.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media attention as the community debates its long-term potential following recent academic recognition for its post-quantum security architecture. Investors are actively discussing the project's institutional utility and price action, with many using the current market movement as an opportunity to accumulate tokens while others remain skeptical about the asset's historical performance.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The Pepe community is rallying around speculation of a potential spot ETF filing by Canary Capital, fueling debates about the token's long-term legitimacy as a blue-chip meme asset. While some investors are actively accumulating on dips in anticipation of a momentum-driven breakout, others remain skeptical, warning of high volatility and broader market risks.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community is actively rallying behind the Jupiter (JUP) ecosystem, with significant focus on the UPDOG meme token as it highlights its presence on the JUP strict list. Participants are emphasizing long-term community resilience and strategic accumulation while leveraging the platform's liquidity tools for trading.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is gaining attention for its focus on long-term conviction, with the community actively highlighting deep on-chain liquidity locks and a treasury-backed model that distinguishes it from short-lived memecoin trends. Investors are coalescing around the project's 'PvE' (Player vs. Everyone) narrative, emphasizing high holder retention and the team's track record as key drivers of stability.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing massive buying momentum and volatility as traders discuss a potential short squeeze fueled by high short interest and market anticipation of upcoming DAO-led buyback programs. The community is actively debating the token's low circulating supply as a catalyst for potential upside while keeping a close watch on key technical levels.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is attracting intense community attention as traders speculate on the potential passage of the Clarity Act, which proponents believe will solidify the token's status as a digital commodity and unlock its utility for institutional payments. While many users remain optimistic about the project's long-term infrastructure role, the discussion is polarized by deep frustration over prolonged price stagnation, accusations of artificial volume manipulation, and skepticism regarding the timing of enterprise adoption.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

<ul class="summary-bullets"><li>The firm stated that the stock is deeply undervalued, with a discounted cash flow estimate of around $30 per share.</li><li>Investors are awaiting extended phase 3 data for CAN-2409 in prostate cancer, as well as from the late-stage trial in non-small cell lung cancer.</li><li>Last month, Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer.</li></ul>Shares of Candel Therapeutics (CADL) drew strong retail interest on Monday after a bullish brokerage call labeled the stock “significantly undervalued,” with optimism building ahead of key trial data in lung and prostate cancer.Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly. The brokerage expressed strong confidence in the stock’s outlook, stating that the shares are “deeply undervalued”, pointing to a discounted cash flow (DCF) estimate of around $30 per share and peak sales potential of $2.4 billion in prostate cancer.This represents a potential 370% upside from the stock’s Friday closing price of $6.37, when the stock recorded its highest intraday gains in more than 16 months. <a href="https://stocktwits.com/symbol/CADL">CADL shares</a> traded 0.5% lower in Monday’s pre-market.Cantor said the bullish view is backed by positive Phase 3 data, clear regulatory progress under a Special Protocol Agreement, limited competition, and a manageable safety profile. Additional upside could come from the company’s lung cancer program, which is advancing into late-stage trials.<h2 class="st-heading-2">CAN-2409 Shows Promise</h2>Last month, Candel Therapeutics reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer. After an additional year of follow-up, 50% of patients were still alive at two years, despite a poor response to prior treatments, the firm said.The therapy also showed improved survival compared with standard care and remained well-tolerated. Researchers found it helped activate the immune system and turn previously unresponsive tumors into ones that could respond to treatment.Extended phase 3 results for CAN-2409 in prostate cancer are <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">expected</a> at the American Urological Association 2026 meeting in May. Investors in Candel Therapeutics are waiting for updates on its late-stage trial in non-small cell lung cancer and on other programs such as CAN-3110.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volume on the platform surged by around 70% over a 24-hour period, according to Stocktwits data.One user said the current share price offers a “tremendous opportunity.”<stembedurl>https://stocktwits.com/drizz/message/650754597</stembedurl>Year-to-date, the stock has gained around 7%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-price-dropping-another-3-000-could-wipe-out-all-ceasefire-gains/cZBdJ8WRIyt">BTC Price Dropping Another $3,000 Could Wipe Out All Ceasefire Gains, Analyst Warns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL Stock Gets A Bullish Call Just Weeks Before Crucial Prostate Cancer Data Reveal

Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly.

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside?

Equity

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned a consensus recommendation of "Hold" from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and...

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the company, MarketBeat...

FY2030 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to...

Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7%

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling...

Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL

Portolan Capital Management LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 14.7% during the third quarter, according to the company in its most recent Form 13F...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc